title: Retroviral integrase inhibitors year 2000: update and perspectives.
abstract: HIV-1 integrase is an essential enzyme for retroviral replication and a rational target for the design of anti-AIDS drugs. A number of inhibitors have been reported in the past 8 years. This review focuses on the recent developments in the past 2 years. There are now several inhibitors with known sites of actions and antiviral activity. The challenge is to convert these leads into drugs that will selectively target integrase in vivo, and can be added to our antiviral armamentarium.
authors.affiliation: Laboratory of Molecular Pharmacology, Division of Basic Sciences, National Cancer Institute, Bethesda, MD 20892-4255, USA. pommier@nih.gov
authors.forename: Y
authors.initials: Y
authors.lastname: Pommier
authors.forename: C
authors.initials: C
authors.lastname: Marchand
authors.forename: N
authors.initials: N
authors.lastname: Neamati
mesh_terms: D019380:Anti-HIV Agents / Q000737:chemistry / Q000378:metabolism; D019427:HIV Integrase / Q000737:chemistry / Q000378:metabolism; D019428:HIV Integrase Inhibitors / Q000737:chemistry / Q000378:metabolism; D015497:HIV-1 / Q000201:enzymology; D006801:Humans
chemical_list: D019380:Anti-HIV Agents; D019428:HIV Integrase Inhibitors; D019427:HIV Integrase